The CaMK Family Differentially Promotes Necroptosis and Mouse Cardiac Graft Injury and Rejection
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25084428 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Haitao Lu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Matthew Mailing Centre for Translational Transplantation Studies, London Health Sciences Centre, London, ON N6A 5A5, Canada. Hauptthemen laut MEDLINE: Necroptosis, Graft Rejection, Heart Transplantation, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Organ transplantation is associated with various forms of programmed cell death which can accelerate transplant injury and rejection. Targeting cell death in donor organs may represent a novel strategy for preventing allograft injury. We have previously demonstrated that necroptosis plays a key role in promoting transplant injury. Recently, we have found that mitochondria function is linked to necroptosis. However, it remains unknown how necroptosis signaling pathways regulate mitochondrial function during necroptosis. In this study, we investigated the receptor-interacting protein kinase 3 (RIPK3) mediated mitochondrial dysfunction and necroptosis. We demonstrate that the calmodulin-dependent protein kinase (CaMK) family members CaMK1, 2, and 4 form a complex with RIPK3 in mouse cardiac endothelial cells, to promote trans-phosphorylation during necroptosis. CaMK1 and 4 directly activated the dynamin-related protein-1 (Drp1), while CaMK2 indirectly activated Drp1 via the phosphoglycerate mutase 5 (PGAM5). The inhibition of CaMKs restored mitochondrial function and effectively prevented endothelial cell death. CaMKs inhibition inhibited activation of CaMKs and Drp1, and cell death and heart tissue injury (n = 6/group, p < 0.01) in a murine model of cardiac transplantation. Importantly, the inhibition of CaMKs greatly prolonged heart graft survival (n = 8/group, p < 0.01). In conclusion, CaMK family members orchestrate cell death in two different pathways and may be potential therapeutic targets in preventing cell death and transplant injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Matthew Mailing Centre for Translational Transplantation Studies, London Health Sciences Centre, London, ON N6A 5A5, Canada.
- Department of Pathology, Western University, London, ON N6A 3K7, Canada.
- Department of Microbiology and Immunology, Western University, London, ON N6A 3K7, Canada.
- Multi-Organ Transplant Program, London Health Sciences Centre, London, ON N6A 5A5, Canada.
- Division of Nephrology, Department of Medicine, Western University, London, ON N6A 3K7, Canada.
ORCID-Profile: Haitao Lu, Lakshman Gunaratnam, Zhu-Xu Zhang
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Lu, H., Jiang, J., Min, J., Huang, X., McLeod, P., Liu, W., Haig, A., Gunaratnam, L., Jevnikar, A. M., & Zhang, Z. X. (2024). The CaMK Family Differentially Promotes Necroptosis and Mouse Cardiac Graft Injury and Rejection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084428
Vancouver
Lu H, Jiang J, Min J, Huang X, McLeod P, Liu W, et al. The CaMK Family Differentially Promotes Necroptosis and Mouse Cardiac Graft Injury and Rejection. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084428
BibTeX
@article{Lu2024,
author = {Lu, Haitao and Jiang, Jifu and Min, Jeffery and Huang, Xuyan and McLeod, Patrick and Liu, Weihua and Haig, Aaron and Gunaratnam, Lakshman and Jevnikar, Anthony M and Zhang, Zhu-Xu},
title = {The CaMK Family Differentially Promotes Necroptosis and Mouse Cardiac Graft Injury and Rejection},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25084428}
}
EUVIMED